panobinostat + lenalidomide + dexamethasone

This drug is a **combination therapy** consisting of panobinostat (a histone deacetylase inhibitor), lenalidomide (an immunomodulatory agent), and dexamethasone (a synthetic glucocorticoid corticosteroid), primarily investigated for the treatment of **multiple myeloma** and relapsed/refractory Hodgkin lymphoma. Panobinostat alters protein acetylation, influencing gene expression and leading to cell cycle arrest and apoptosis in cancer cells[2][3][4]. Lenalidomide enhances the immune response against tumor cells, inhibits angiogenesis, and modulates cytokine production[2][3][4]. Dexamethasone suppresses inflammation and immune responses, augmenting antitumor effects and reducing adverse reactions when used in combination. Preclinical and clinical evidence shows that the triple combination provides synergistic antimyeloma activity, with inhibition of tumor growth, increased apoptosis, and modulation of genes distinct from single agents alone[3][4]. Unique mechanistic profiles and enhanced efficacy have been demonstrated in various models and early-phase clinical studies[4].

Other names

PLDpanobinostat-lenalidomide-dexamethasone